Feed

Insulin resistance (IR) is an underrecognized feature of type 1 diabetes (T1D), present even in lean individuals. Rising obesity rates have further amplified this burden, creating a mixed metabolic phenotype that accelerates cardiorenal disease. Paradoxically, despite fewer traditional cardiovascular risk factors, individuals with T1D experience higher rates of cardiorenal complications than those with type 2 diabetes, a gap not fully explained by glycemic control. This article examines the epidemiologic, pathophysiologic, and mechanistic underpinnings of this hidden cardiorenal risk, including key drivers of end-organ damage. Broader therapeutic interventions targeting IR in T1D are essential to prevent future cardiorenal disease.